Fulgent Genetics, Inc. (FLGT) 10-Year Financial Performance & Capital Metrics

FLGT • • Industrial / General

HealthcareDiagnostics & ResearchClinical Laboratory ServicesGeneral Clinical Laboratories

AboutFulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.Show more

Revenue $283M -2.0%
EBITDA -$49M +71.1%
Net Income -$43M +74.6%
EPS (Diluted) -1.41 +75.0%
Gross Margin 37.82% +4.7%
EBITDA Margin -17.28% +70.5%
Operating Margin -26.08% +61.4%
Net Margin -15.07% +74.0%
ROE -3.78% +73.0%
ROIC -5.2% +59.6%
Debt/Equity 0.01 -44.3%
Interest Coverage -434.81 -8.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 54.2%
✓Healthy 5Y average net margin of 10.4%
✓Trading at only 0.8x book value

✗Weaknesses

✗Negative free cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y71.63%

5Y54.19%

3Y-34.15%

TTM13.6%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM73.94%

EPS CAGR

10Y-

5Y-

3Y-

TTM75%

ROCE

10Y Avg-0.2%

5Y Avg31.65%

3Y Avg-2.62%

Latest-6.4%

Peer Comparison

General Clinical Laboratories

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
DGXQuest Diagnostics Incorporated	21.16B	190.26	24.74	6.7%	8.93%	13.14%	4.29%	1.03
OPKOPKO Health, Inc.	982.66M	1.28	-16.69	-17.41%	-21.93%	-10.79%		0.37
FLGTFulgent Genetics, Inc.	885.64M	28.65	-20.32	-1.99%	-13.62%	-3.84%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	9.58M	18.28M	18.73M	21.36M	32.53M	421.71M	992.58M	618.97M	289.21M	283.47M
Revenue Growth %	6.49%	0.91%	0.02%	0.14%	0.52%	11.96%	1.35%	-0.38%	-0.53%	-0.02%
Cost of Goods Sold+	5.07M	6.72M	8.55M	10.69M	14.11M	89.81M	215.53M	252.07M	184.76M	176.25M
COGS % of Revenue	0.53%	0.37%	0.46%	0.5%	0.43%	0.21%	0.22%	0.41%	0.64%	0.62%
Gross Profit+	4.51M	11.55M	10.18M	10.66M	18.42M	331.9M	777.05M	366.9M	104.46M	107.22M
Gross Margin %	0.47%	0.63%	0.54%	0.5%	0.57%	0.79%	0.78%	0.59%	0.36%	0.38%
Gross Profit Growth %	12.18%	1.56%	-0.12%	0.05%	0.73%	17.02%	1.34%	-0.53%	-0.72%	0.03%
Operating Expenses+	9.52M	10.64M	13.58M	15.72M	18.85M	41.75M	101.1M	188.37M	299.99M	181.13M
OpEx % of Revenue	0.99%	0.58%	0.72%	0.74%	0.58%	0.1%	0.1%	0.3%	1.04%	0.64%
Selling, General & Admin	5.09M	7.08M	9.44M	10.19M	12.31M	30.17M	75.17M	149.99M	130.47M	124.35M
SG&A % of Revenue	0.53%	0.39%	0.5%	0.48%	0.38%	0.07%	0.08%	0.24%	0.45%	0.44%
Research & Development	4.43M	3.56M	4.22M	5.53M	6.54M	11.58M	24.22M	28.91M	41.44M	48.82M
R&D % of Revenue	0.46%	0.19%	0.23%	0.26%	0.2%	0.03%	0.02%	0.05%	0.14%	0.17%
Other Operating Expenses	0	0	0	0	0	0	1.71M	9.47M	128.08M	7.96M
Operating Income+	-5.01M	919K	-3.48M	-5.07M	-428K	290.16M	675.95M	178.53M	-195.53M	-73.92M
Operating Margin %	-0.52%	0.05%	-0.19%	-0.24%	-0.01%	0.69%	0.68%	0.29%	-0.68%	-0.26%
Operating Income Growth %	-4.06%	1.18%	-4.79%	-0.46%	0.92%	678.94%	1.33%	-0.74%	-2.1%	0.62%
EBITDA+	-4.44M	2.09M	-1.75M	-2.91M	1.68M	293.12M	686.96M	211.19M	-169.39M	-48.99M
EBITDA Margin %	-0.46%	0.11%	-0.09%	-0.14%	0.05%	0.7%	0.69%	0.34%	-0.59%	-0.17%
EBITDA Growth %	-4.59%	1.47%	-1.84%	-0.66%	1.58%	173.58%	1.34%	-0.69%	-1.8%	0.71%
D&A (Non-Cash Add-back)	575K	1.17M	1.73M	2.16M	2.11M	2.96M	11M	32.66M	26.14M	24.93M
EBIT	-5.01M	918K	-3.48M	-5.07M	-428K	290.16M	675.95M	185.04M	-173.6M	-73.92M
Net Interest Income+	27K	-5.39M	481K	434K	837K	1.53M	1.35M	4.61M	21.12M	31.13M
Interest Income	27K	0	481K	434K	837K	1.53M	1.35M	5.62M	21.61M	31.3M
Interest Expense	0	5.39M	0	0	0	0	0	1.01M	488K	170K
Other Income/Expense	27K	-5.39M	481K	434K	60K	-3.32M	5.08M	5.5M	21.44M	21.96M
Pretax Income+	-4.99M	-4.47M	-3M	-4.64M	-368K	286.84M	681.03M	184.03M	-174.09M	-51.96M
Pretax Margin %	-0.52%	-0.24%	-0.16%	-0.22%	-0.01%	0.68%	0.69%	0.3%	-0.6%	-0.18%
Income Tax+	3.33M	920K	-1.01M	36K	43K	72.53M	174.79M	42.1M	1.15M	-8.14M
Effective Tax Rate %	1.67%	1.2%	0.84%	1.21%	1.12%	0.75%	0.74%	0.78%	0.96%	0.82%
Net Income+	-8.31M	-5.35M	-2.51M	-5.61M	-411K	214.31M	507.36M	143.4M	-167.82M	-42.71M
Net Margin %	-0.87%	-0.29%	-0.13%	-0.26%	-0.01%	0.51%	0.51%	0.23%	-0.58%	-0.15%
Net Income Growth %	-0.94%	0.36%	0.53%	-1.23%	0.93%	522.44%	1.37%	-0.72%	-2.17%	0.75%
Net Income (Continuing)	-4.99M	-5.39M	-1.99M	-5.61M	-411K	214.31M	506.24M	141.92M	-175.24M	-43.82M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	7.13M	3.19M	-2.81M	-4.07M
EPS (Diluted)+	-0.64	-0.30	-0.15	-0.25	-0.02	8.91	16.26	4.63	-5.63	-1.41
EPS Growth %	-0.88%	0.53%	0.5%	-0.67%	0.92%	446.5%	0.82%	-0.72%	-2.22%	0.75%
EPS (Basic)	-0.64	-0.30	-0.15	-0.25	-0.02	9.44	17.13	4.76	-5.63	-1.41
Diluted Shares Outstanding	12.77M	17.68M	17.74M	17.98M	18.71M	24.06M	30.98M	30.96M	29.78M	30.23M
Basic Shares Outstanding	12.77M	17.68M	17.74M	17.98M	18.71M	22.69M	29.41M	30.1M	29.78M	30.23M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.93M	50.83M	45.37M	43.37M	37.08M	523.62M	611.96M	627.87M	507.85M	353.57M
Cash & Short-Term Investments	489K	46.47M	41.37M	37.42M	28.27M	299.37M	450.5M	526.24M	424.15M	258.11M
Cash Only	489K	7.9M	6.49M	6.74M	11.96M	87.43M	164.89M	79.51M	97.47M	55.14M
Short-Term Investments	0	38.57M	34.88M	30.68M	16.3M	211.94M	285.61M	446.73M	326.68M	202.96M
Accounts Receivable	2.15M	4.36M	4.07M	6.24M	7.2M	204.06M	143.29M	75.11M	57.45M	77.03M
Days Sales Outstanding	82.14	87.16	79.33	106.61	80.78	176.62	52.69	44.29	72.5	99.18
Inventory	212K	322K	231K	314K	277K	16.49M	12.21M	4.28M	0	8.38M
Days Inventory Outstanding	15.27	17.49	9.86	10.72	7.17	67.02	20.67	6.2	-	17.36
Other Current Assets	221K	322K	231K	0	0	0	0	0	5.83M	0
Total Non-Current Assets+	2.9M	7.21M	11.58M	11.64M	51.68M	176.84M	666.76M	758.18M	727.48M	866.39M
Property, Plant & Equipment	2.47M	6.23M	7.27M	6.45M	8.61M	40.2M	62.29M	81.35M	95.62M	105.55M
Fixed Asset Turnover	3.88x	2.93x	2.58x	3.31x	3.78x	10.49x	15.94x	7.61x	3.02x	2.69x
Goodwill	0	0	0	0	0	0	50.9M	143.03M	22.05M	22.05M
Intangible Assets	0	0	0	0	0	0	35.91M	150.64M	143.05M	134.98M
Long-Term Investments	0	25.6M	16.82M	7.9M	42.82M	132.5M	507.01M	339.03M	444.01M	570.35M
Other Non-Current Assets	433K	977K	4.31M	-2.7M	251K	4.14M	10.65M	44.12M	22.75M	33.46M
Total Assets+	5.83M	58.04M	56.95M	55.02M	88.76M	700.46M	1.28B	1.39B	1.24B	1.22B
Asset Turnover	1.64x	0.31x	0.33x	0.39x	0.37x	0.60x	0.78x	0.45x	0.23x	0.23x
Asset Growth %	1.75%	8.95%	-0.02%	-0.03%	0.61%	6.89%	0.83%	0.08%	-0.11%	-0.01%
Total Current Liabilities+	686K	3.56M	2.92M	2.75M	3.72M	130.12M	105.31M	88.11M	73.02M	72.9M
Accounts Payable	314K	2.76M	2.09M	1.31M	1.58M	26.49M	20.49M	23.09M	15.36M	18.36M
Days Payables Outstanding	22.61	149.67	89.17	44.82	40.91	107.65	34.71	33.44	30.34	38.03
Short-Term Debt	0	0	0	0	0	15.02M	21.28M	20.64M	1.18M	412K
Deferred Revenue (Current)	0	0	0	0	365K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	173K	0	0	166K	0	-185K	10.68M	5.3M	164K	5.8M
Current Ratio	4.27x	14.27x	15.51x	15.80x	9.96x	4.02x	5.81x	7.13x	6.96x	4.85x
Quick Ratio	3.96x	14.18x	15.43x	15.69x	9.89x	3.90x	5.70x	7.08x	6.96x	4.74x
Cash Conversion Cycle	74.8	-45.03	0.02	72.51	47.04	135.99	38.66	17.05	-	78.52
Total Non-Current Liabilities+	0	245K	6K	14K	2.26M	959K	7.53M	28.07M	29.02M	17.91M
Long-Term Debt	0	0	0	0	0	0	0	3.37M	2.96M	2.49M
Capital Lease Obligations	0	0	0	0	2.26M	568K	0	8.79M	7.15M	4.12M
Deferred Tax Liabilities	0	243K	820K	718K	0	0	0	0	7.96M	6.37M
Other Non-Current Liabilities	0	2K	6K	14K	0	391K	7.53M	15.9M	10.95M	4.92M
Total Liabilities	686K	3.56M	2.92M	2.75M	5.98M	131.07M	112.84M	116.18M	102.04M	90.81M
Total Debt+	0	0	0	0	2.68M	15.85M	21.28M	38.94M	15.25M	8.47M
Net Debt	-489K	-7.9M	-6.49M	-6.74M	-9.29M	-71.57M	-143.61M	-40.57M	-82.22M	-46.68M
Debt / Equity	-	-	-	-	0.03x	0.03x	0.02x	0.03x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	1.59x	0.05x	0.03x	0.18x	-	-
Net Debt / EBITDA	-	-3.78x	-	-	-5.53x	-0.24x	-0.21x	-0.19x	-	-
Interest Coverage	-	0.17x	-	-	-	-	-	176.24x	-400.67x	-434.81x
Total Equity+	5.15M	54.48M	54.03M	52.27M	82.78M	569.39M	1.17B	1.27B	1.13B	1.13B
Equity Growth %	2.06%	9.59%	-0.01%	-0.03%	0.58%	5.88%	1.05%	0.09%	-0.11%	-0%
Book Value per Share	0.40	3.08	3.05	2.91	4.42	23.67	37.64	41.01	38.05	37.35
Total Shareholders' Equity	5.15M	54.48M	54.03M	52.27M	82.78M	569.39M	1.16B	1.27B	1.14B	1.13B
Common Stock	12.32M	2K	2K	2K	2K	3K	3K	3K	3K	3K
Retained Earnings	-53.16M	-55.15M	-57.66M	-63.02M	-63.43M	150.88M	657.6M	801M	633.17M	590.47M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-900K	-103K	-44K	-35K	146K	438K	-759K	-20.9M	1.21M	-368K
Minority Interest	0	0	0	0	0	0	7.13M	3.19M	-2.81M	-4.07M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-969K	4.41M	1.33M	-675K	5.52M	140.63M	538.58M	253.52M	27M	21.06M
Operating CF Margin %	-0.1%	0.24%	0.07%	-0.03%	0.17%	0.33%	0.54%	0.41%	0.09%	0.07%
Operating CF Growth %	0.78%	5.55%	-0.7%	-1.51%	9.17%	24.49%	2.83%	-0.53%	-0.89%	-0.22%
Net Income	-4.99M	-5.39M	-2.51M	-5.61M	-411K	214.31M	506.24M	141.92M	-175.24M	-43.82M
Depreciation & Amortization	575K	1.17M	1.73M	2.16M	2.52M	2.96M	11M	32.66M	26.14M	24.93M
Stock-Based Compensation	8.16M	4.65M	2.12M	2.3M	0	8.16M	15.88M	32.64M	42.92M	44.48M
Deferred Taxes	-3.33M	246K	-336K	36K	-21K	-1.4M	-7.84M	831K	7.61M	-5.15M
Other Non-Cash Items	362K	5.58M	1.04M	1.67M	4.34M	8.05M	15.97M	43.46M	122.73M	7.86M
Working Capital Changes	-1.75M	-1.86M	-714K	-1.24M	-915K	-91.45M	-2.68M	2M	2.84M	-7.24M
Change in Receivables	-1.78M	-2.32M	214K	-1.97M	-839K	-178.48M	42.3M	68.64M	2.39M	-16.3M
Change in Inventory	-2.35M	-23.45M	-30.49M	-36.18M	0	0	0	0	0	0
Change in Payables	132K	1.09M	-363K	102K	-329K	22.62M	-12.21M	-25.34M	-6.9M	3.07M
Cash from Investing+	-2.21M	-42.8M	-2.05M	950K	-29.05M	-326.44M	-546.55M	-261.31M	38.9M	-58.35M
Capital Expenditures	-2.1M	-3.79M	-5.36M	-2.83M	-1.18M	-36.51M	-23.81M	-18.77M	-22.21M	-40.31M
CapEx % of Revenue	0.22%	0.21%	0.29%	0.13%	0.04%	0.09%	0.02%	0.03%	0.08%	0.14%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-105K	10K	-2.46M	-510K	0	8K	31K	412K	775K	313K
Cash from Financing+	3.5M	45.79M	-770K	15K	28.77M	261.25M	85.41M	-77.14M	-47.78M	-4.85M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-4.59M	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	3.5M	-1.41M	-770K	15K	0	104K	96K	31K	3K	51K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.07M	617K	-4.03M	-3.51M	4.33M	104.12M	514.73M	234.75M	4.8M	-19.25M
FCF Margin %	-0.32%	0.03%	-0.21%	-0.16%	0.13%	0.25%	0.52%	0.38%	0.02%	-0.07%
FCF Growth %	0.4%	1.2%	-7.52%	0.13%	2.24%	23.02%	3.94%	-0.54%	-0.98%	-5.01%
FCF per Share	-0.24	0.03	-0.23	-0.20	0.23	4.33	16.62	7.58	0.16	-0.64
FCF Conversion (FCF/Net Income)	0.12x	-0.82x	-0.53x	0.12x	-13.42x	0.66x	1.06x	1.77x	-0.16x	-0.49x
Interest Paid	0	0	0	0	0	0	0	0	960K	512K
Taxes Paid	0	550K	757K	1K	0	20.61M	237.07M	56.19M	3.26M	27.59M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-243.46%	-17.94%	-4.63%	-10.55%	-0.61%	65.72%	58.48%	11.77%	-13.97%	-3.78%
Return on Invested Capital (ROIC)	-121.87%	2.69%	-5.55%	-8.17%	-0.54%	76.18%	66.7%	11.89%	-12.86%	-5.2%
Gross Margin	47.07%	63.22%	54.35%	49.94%	56.63%	78.7%	78.29%	59.28%	36.12%	37.82%
Net Margin	-86.82%	-29.26%	-13.4%	-26.25%	-1.26%	50.82%	51.12%	23.17%	-58.03%	-15.07%
Debt / Equity	-	-	-	-	0.03x	0.03x	0.02x	0.03x	0.01x	0.01x
Interest Coverage	-	0.17x	-	-	-	-	-	176.24x	-400.67x	-434.81x
FCF Conversion	0.12x	-0.82x	-0.53x	0.12x	-13.42x	0.66x	1.06x	1.77x	-0.16x	-0.49x
Revenue Growth	649.3%	90.85%	2.48%	14.03%	52.31%	1196.46%	135.37%	-37.64%	-53.27%	-1.99%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024
Laboratory Services	-	-	-	-	-	-	-	289.21M	283.47M
Laboratory Services Growth	-	-	-	-	-	-	-	-	-1.99%

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	8.26M	9.02M	12.58M	25.01M	415.33M	978.98M	603.15M	268.98M	259.13M
UNITED STATES Growth	-	9.28%	39.39%	98.86%	1560.41%	135.71%	-38.39%	-55.40%	-3.66%
Non-US	-	-	-	-	-	-	15.82M	20.24M	24.34M
Non-US Growth	-	-	-	-	-	-	-	27.91%	20.27%
CHINA	3.24M	2.61M	109K	-	-	-	-	-	12.64M
CHINA Growth	-	-19.35%	-95.83%	-	-	-	-	-	-
Other Countries	2.98M	3M	4.68M	5.27M	4.65M	-	-	-	11.7M
Other Countries Growth	-	0.74%	55.91%	12.61%	-11.69%	-	-	-	-
Non Us	-	-	-	-	-	13.61M	-	-	-
Non Us Growth	-	-	-	-	-	-	-	-	-
CANADA	3.8M	4.09M	3.98M	2.25M	1.73M	-	-	-	-
CANADA Growth	-	7.71%	-2.62%	-43.65%	-23.16%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Fulgent Genetics, Inc. (FLGT) reported $315.5M in revenue for fiscal year 2024. This represents a 24591% increase from $1.3M in 2014.

Fulgent Genetics, Inc. (FLGT) saw revenue decline by 2.0% over the past year.

Fulgent Genetics, Inc. (FLGT) reported a net loss of $43.0M for fiscal year 2024.

Dividend & Returns

Fulgent Genetics, Inc. (FLGT) has a return on equity (ROE) of -3.8%. Negative ROE indicates the company is unprofitable.

Fulgent Genetics, Inc. (FLGT) had negative free cash flow of $19.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Fulgent Genetics, Inc. (FLGT) 10-Year Financial Performance & Capital Metrics

FLGT • • Industrial / General

HealthcareDiagnostics & ResearchClinical Laboratory ServicesGeneral Clinical Laboratories

Revenue $283M -2.0%
EBITDA -$49M +71.1%
Net Income -$43M +74.6%
EPS (Diluted) -1.41 +75.0%
Gross Margin 37.82% +4.7%
EBITDA Margin -17.28% +70.5%
Operating Margin -26.08% +61.4%
Net Margin -15.07% +74.0%
ROE -3.78% +73.0%
ROIC -5.2% +59.6%
Debt/Equity 0.01 -44.3%
Interest Coverage -434.81 -8.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Strong 5Y sales CAGR of 54.2%
✓Healthy 5Y average net margin of 10.4%
✓Trading at only 0.8x book value

✗Weaknesses

✗Negative free cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y71.63%

5Y54.19%

3Y-34.15%

TTM13.6%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM73.94%

EPS CAGR

10Y-

5Y-

3Y-

TTM75%

ROCE

10Y Avg-0.2%

5Y Avg31.65%

3Y Avg-2.62%

Latest-6.4%

Peer Comparison

General Clinical Laboratories

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
DGXQuest Diagnostics Incorporated	21.16B	190.26	24.74	6.7%	8.93%	13.14%	4.29%	1.03
OPKOPKO Health, Inc.	982.66M	1.28	-16.69	-17.41%	-21.93%	-10.79%		0.37
FLGTFulgent Genetics, Inc.	885.64M	28.65	-20.32	-1.99%	-13.62%	-3.84%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	9.58M	18.28M	18.73M	21.36M	32.53M	421.71M	992.58M	618.97M	289.21M	283.47M
Revenue Growth %	6.49%	0.91%	0.02%	0.14%	0.52%	11.96%	1.35%	-0.38%	-0.53%	-0.02%
Cost of Goods Sold+	5.07M	6.72M	8.55M	10.69M	14.11M	89.81M	215.53M	252.07M	184.76M	176.25M
COGS % of Revenue	0.53%	0.37%	0.46%	0.5%	0.43%	0.21%	0.22%	0.41%	0.64%	0.62%
Gross Profit+	4.51M	11.55M	10.18M	10.66M	18.42M	331.9M	777.05M	366.9M	104.46M	107.22M
Gross Margin %	0.47%	0.63%	0.54%	0.5%	0.57%	0.79%	0.78%	0.59%	0.36%	0.38%
Gross Profit Growth %	12.18%	1.56%	-0.12%	0.05%	0.73%	17.02%	1.34%	-0.53%	-0.72%	0.03%
Operating Expenses+	9.52M	10.64M	13.58M	15.72M	18.85M	41.75M	101.1M	188.37M	299.99M	181.13M
OpEx % of Revenue	0.99%	0.58%	0.72%	0.74%	0.58%	0.1%	0.1%	0.3%	1.04%	0.64%
Selling, General & Admin	5.09M	7.08M	9.44M	10.19M	12.31M	30.17M	75.17M	149.99M	130.47M	124.35M
SG&A % of Revenue	0.53%	0.39%	0.5%	0.48%	0.38%	0.07%	0.08%	0.24%	0.45%	0.44%
Research & Development	4.43M	3.56M	4.22M	5.53M	6.54M	11.58M	24.22M	28.91M	41.44M	48.82M
R&D % of Revenue	0.46%	0.19%	0.23%	0.26%	0.2%	0.03%	0.02%	0.05%	0.14%	0.17%
Other Operating Expenses	0	0	0	0	0	0	1.71M	9.47M	128.08M	7.96M
Operating Income+	-5.01M	919K	-3.48M	-5.07M	-428K	290.16M	675.95M	178.53M	-195.53M	-73.92M
Operating Margin %	-0.52%	0.05%	-0.19%	-0.24%	-0.01%	0.69%	0.68%	0.29%	-0.68%	-0.26%
Operating Income Growth %	-4.06%	1.18%	-4.79%	-0.46%	0.92%	678.94%	1.33%	-0.74%	-2.1%	0.62%
EBITDA+	-4.44M	2.09M	-1.75M	-2.91M	1.68M	293.12M	686.96M	211.19M	-169.39M	-48.99M
EBITDA Margin %	-0.46%	0.11%	-0.09%	-0.14%	0.05%	0.7%	0.69%	0.34%	-0.59%	-0.17%
EBITDA Growth %	-4.59%	1.47%	-1.84%	-0.66%	1.58%	173.58%	1.34%	-0.69%	-1.8%	0.71%
D&A (Non-Cash Add-back)	575K	1.17M	1.73M	2.16M	2.11M	2.96M	11M	32.66M	26.14M	24.93M
EBIT	-5.01M	918K	-3.48M	-5.07M	-428K	290.16M	675.95M	185.04M	-173.6M	-73.92M
Net Interest Income+	27K	-5.39M	481K	434K	837K	1.53M	1.35M	4.61M	21.12M	31.13M
Interest Income	27K	0	481K	434K	837K	1.53M	1.35M	5.62M	21.61M	31.3M
Interest Expense	0	5.39M	0	0	0	0	0	1.01M	488K	170K
Other Income/Expense	27K	-5.39M	481K	434K	60K	-3.32M	5.08M	5.5M	21.44M	21.96M
Pretax Income+	-4.99M	-4.47M	-3M	-4.64M	-368K	286.84M	681.03M	184.03M	-174.09M	-51.96M
Pretax Margin %	-0.52%	-0.24%	-0.16%	-0.22%	-0.01%	0.68%	0.69%	0.3%	-0.6%	-0.18%
Income Tax+	3.33M	920K	-1.01M	36K	43K	72.53M	174.79M	42.1M	1.15M	-8.14M
Effective Tax Rate %	1.67%	1.2%	0.84%	1.21%	1.12%	0.75%	0.74%	0.78%	0.96%	0.82%
Net Income+	-8.31M	-5.35M	-2.51M	-5.61M	-411K	214.31M	507.36M	143.4M	-167.82M	-42.71M
Net Margin %	-0.87%	-0.29%	-0.13%	-0.26%	-0.01%	0.51%	0.51%	0.23%	-0.58%	-0.15%
Net Income Growth %	-0.94%	0.36%	0.53%	-1.23%	0.93%	522.44%	1.37%	-0.72%	-2.17%	0.75%
Net Income (Continuing)	-4.99M	-5.39M	-1.99M	-5.61M	-411K	214.31M	506.24M	141.92M	-175.24M	-43.82M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	7.13M	3.19M	-2.81M	-4.07M
EPS (Diluted)+	-0.64	-0.30	-0.15	-0.25	-0.02	8.91	16.26	4.63	-5.63	-1.41
EPS Growth %	-0.88%	0.53%	0.5%	-0.67%	0.92%	446.5%	0.82%	-0.72%	-2.22%	0.75%
EPS (Basic)	-0.64	-0.30	-0.15	-0.25	-0.02	9.44	17.13	4.76	-5.63	-1.41
Diluted Shares Outstanding	12.77M	17.68M	17.74M	17.98M	18.71M	24.06M	30.98M	30.96M	29.78M	30.23M
Basic Shares Outstanding	12.77M	17.68M	17.74M	17.98M	18.71M	22.69M	29.41M	30.1M	29.78M	30.23M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.93M	50.83M	45.37M	43.37M	37.08M	523.62M	611.96M	627.87M	507.85M	353.57M
Cash & Short-Term Investments	489K	46.47M	41.37M	37.42M	28.27M	299.37M	450.5M	526.24M	424.15M	258.11M
Cash Only	489K	7.9M	6.49M	6.74M	11.96M	87.43M	164.89M	79.51M	97.47M	55.14M
Short-Term Investments	0	38.57M	34.88M	30.68M	16.3M	211.94M	285.61M	446.73M	326.68M	202.96M
Accounts Receivable	2.15M	4.36M	4.07M	6.24M	7.2M	204.06M	143.29M	75.11M	57.45M	77.03M
Days Sales Outstanding	82.14	87.16	79.33	106.61	80.78	176.62	52.69	44.29	72.5	99.18
Inventory	212K	322K	231K	314K	277K	16.49M	12.21M	4.28M	0	8.38M
Days Inventory Outstanding	15.27	17.49	9.86	10.72	7.17	67.02	20.67	6.2	-	17.36
Other Current Assets	221K	322K	231K	0	0	0	0	0	5.83M	0
Total Non-Current Assets+	2.9M	7.21M	11.58M	11.64M	51.68M	176.84M	666.76M	758.18M	727.48M	866.39M
Property, Plant & Equipment	2.47M	6.23M	7.27M	6.45M	8.61M	40.2M	62.29M	81.35M	95.62M	105.55M
Fixed Asset Turnover	3.88x	2.93x	2.58x	3.31x	3.78x	10.49x	15.94x	7.61x	3.02x	2.69x
Goodwill	0	0	0	0	0	0	50.9M	143.03M	22.05M	22.05M
Intangible Assets	0	0	0	0	0	0	35.91M	150.64M	143.05M	134.98M
Long-Term Investments	0	25.6M	16.82M	7.9M	42.82M	132.5M	507.01M	339.03M	444.01M	570.35M
Other Non-Current Assets	433K	977K	4.31M	-2.7M	251K	4.14M	10.65M	44.12M	22.75M	33.46M
Total Assets+	5.83M	58.04M	56.95M	55.02M	88.76M	700.46M	1.28B	1.39B	1.24B	1.22B
Asset Turnover	1.64x	0.31x	0.33x	0.39x	0.37x	0.60x	0.78x	0.45x	0.23x	0.23x
Asset Growth %	1.75%	8.95%	-0.02%	-0.03%	0.61%	6.89%	0.83%	0.08%	-0.11%	-0.01%
Total Current Liabilities+	686K	3.56M	2.92M	2.75M	3.72M	130.12M	105.31M	88.11M	73.02M	72.9M
Accounts Payable	314K	2.76M	2.09M	1.31M	1.58M	26.49M	20.49M	23.09M	15.36M	18.36M
Days Payables Outstanding	22.61	149.67	89.17	44.82	40.91	107.65	34.71	33.44	30.34	38.03
Short-Term Debt	0	0	0	0	0	15.02M	21.28M	20.64M	1.18M	412K
Deferred Revenue (Current)	0	0	0	0	365K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	173K	0	0	166K	0	-185K	10.68M	5.3M	164K	5.8M
Current Ratio	4.27x	14.27x	15.51x	15.80x	9.96x	4.02x	5.81x	7.13x	6.96x	4.85x
Quick Ratio	3.96x	14.18x	15.43x	15.69x	9.89x	3.90x	5.70x	7.08x	6.96x	4.74x
Cash Conversion Cycle	74.8	-45.03	0.02	72.51	47.04	135.99	38.66	17.05	-	78.52
Total Non-Current Liabilities+	0	245K	6K	14K	2.26M	959K	7.53M	28.07M	29.02M	17.91M
Long-Term Debt	0	0	0	0	0	0	0	3.37M	2.96M	2.49M
Capital Lease Obligations	0	0	0	0	2.26M	568K	0	8.79M	7.15M	4.12M
Deferred Tax Liabilities	0	243K	820K	718K	0	0	0	0	7.96M	6.37M
Other Non-Current Liabilities	0	2K	6K	14K	0	391K	7.53M	15.9M	10.95M	4.92M
Total Liabilities	686K	3.56M	2.92M	2.75M	5.98M	131.07M	112.84M	116.18M	102.04M	90.81M
Total Debt+	0	0	0	0	2.68M	15.85M	21.28M	38.94M	15.25M	8.47M
Net Debt	-489K	-7.9M	-6.49M	-6.74M	-9.29M	-71.57M	-143.61M	-40.57M	-82.22M	-46.68M
Debt / Equity	-	-	-	-	0.03x	0.03x	0.02x	0.03x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	1.59x	0.05x	0.03x	0.18x	-	-
Net Debt / EBITDA	-	-3.78x	-	-	-5.53x	-0.24x	-0.21x	-0.19x	-	-
Interest Coverage	-	0.17x	-	-	-	-	-	176.24x	-400.67x	-434.81x
Total Equity+	5.15M	54.48M	54.03M	52.27M	82.78M	569.39M	1.17B	1.27B	1.13B	1.13B
Equity Growth %	2.06%	9.59%	-0.01%	-0.03%	0.58%	5.88%	1.05%	0.09%	-0.11%	-0%
Book Value per Share	0.40	3.08	3.05	2.91	4.42	23.67	37.64	41.01	38.05	37.35
Total Shareholders' Equity	5.15M	54.48M	54.03M	52.27M	82.78M	569.39M	1.16B	1.27B	1.14B	1.13B
Common Stock	12.32M	2K	2K	2K	2K	3K	3K	3K	3K	3K
Retained Earnings	-53.16M	-55.15M	-57.66M	-63.02M	-63.43M	150.88M	657.6M	801M	633.17M	590.47M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-900K	-103K	-44K	-35K	146K	438K	-759K	-20.9M	1.21M	-368K
Minority Interest	0	0	0	0	0	0	7.13M	3.19M	-2.81M	-4.07M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-969K	4.41M	1.33M	-675K	5.52M	140.63M	538.58M	253.52M	27M	21.06M
Operating CF Margin %	-0.1%	0.24%	0.07%	-0.03%	0.17%	0.33%	0.54%	0.41%	0.09%	0.07%
Operating CF Growth %	0.78%	5.55%	-0.7%	-1.51%	9.17%	24.49%	2.83%	-0.53%	-0.89%	-0.22%
Net Income	-4.99M	-5.39M	-2.51M	-5.61M	-411K	214.31M	506.24M	141.92M	-175.24M	-43.82M
Depreciation & Amortization	575K	1.17M	1.73M	2.16M	2.52M	2.96M	11M	32.66M	26.14M	24.93M
Stock-Based Compensation	8.16M	4.65M	2.12M	2.3M	0	8.16M	15.88M	32.64M	42.92M	44.48M
Deferred Taxes	-3.33M	246K	-336K	36K	-21K	-1.4M	-7.84M	831K	7.61M	-5.15M
Other Non-Cash Items	362K	5.58M	1.04M	1.67M	4.34M	8.05M	15.97M	43.46M	122.73M	7.86M
Working Capital Changes	-1.75M	-1.86M	-714K	-1.24M	-915K	-91.45M	-2.68M	2M	2.84M	-7.24M
Change in Receivables	-1.78M	-2.32M	214K	-1.97M	-839K	-178.48M	42.3M	68.64M	2.39M	-16.3M
Change in Inventory	-2.35M	-23.45M	-30.49M	-36.18M	0	0	0	0	0	0
Change in Payables	132K	1.09M	-363K	102K	-329K	22.62M	-12.21M	-25.34M	-6.9M	3.07M
Cash from Investing+	-2.21M	-42.8M	-2.05M	950K	-29.05M	-326.44M	-546.55M	-261.31M	38.9M	-58.35M
Capital Expenditures	-2.1M	-3.79M	-5.36M	-2.83M	-1.18M	-36.51M	-23.81M	-18.77M	-22.21M	-40.31M
CapEx % of Revenue	0.22%	0.21%	0.29%	0.13%	0.04%	0.09%	0.02%	0.03%	0.08%	0.14%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-105K	10K	-2.46M	-510K	0	8K	31K	412K	775K	313K
Cash from Financing+	3.5M	45.79M	-770K	15K	28.77M	261.25M	85.41M	-77.14M	-47.78M	-4.85M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	-4.59M	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	3.5M	-1.41M	-770K	15K	0	104K	96K	31K	3K	51K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.07M	617K	-4.03M	-3.51M	4.33M	104.12M	514.73M	234.75M	4.8M	-19.25M
FCF Margin %	-0.32%	0.03%	-0.21%	-0.16%	0.13%	0.25%	0.52%	0.38%	0.02%	-0.07%
FCF Growth %	0.4%	1.2%	-7.52%	0.13%	2.24%	23.02%	3.94%	-0.54%	-0.98%	-5.01%
FCF per Share	-0.24	0.03	-0.23	-0.20	0.23	4.33	16.62	7.58	0.16	-0.64
FCF Conversion (FCF/Net Income)	0.12x	-0.82x	-0.53x	0.12x	-13.42x	0.66x	1.06x	1.77x	-0.16x	-0.49x
Interest Paid	0	0	0	0	0	0	0	0	960K	512K
Taxes Paid	0	550K	757K	1K	0	20.61M	237.07M	56.19M	3.26M	27.59M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-243.46%	-17.94%	-4.63%	-10.55%	-0.61%	65.72%	58.48%	11.77%	-13.97%	-3.78%
Return on Invested Capital (ROIC)	-121.87%	2.69%	-5.55%	-8.17%	-0.54%	76.18%	66.7%	11.89%	-12.86%	-5.2%
Gross Margin	47.07%	63.22%	54.35%	49.94%	56.63%	78.7%	78.29%	59.28%	36.12%	37.82%
Net Margin	-86.82%	-29.26%	-13.4%	-26.25%	-1.26%	50.82%	51.12%	23.17%	-58.03%	-15.07%
Debt / Equity	-	-	-	-	0.03x	0.03x	0.02x	0.03x	0.01x	0.01x
Interest Coverage	-	0.17x	-	-	-	-	-	176.24x	-400.67x	-434.81x
FCF Conversion	0.12x	-0.82x	-0.53x	0.12x	-13.42x	0.66x	1.06x	1.77x	-0.16x	-0.49x
Revenue Growth	649.3%	90.85%	2.48%	14.03%	52.31%	1196.46%	135.37%	-37.64%	-53.27%	-1.99%

Revenue by Segment

	2016	2017	2018	2019	2020	2021	2022	2023	2024
Laboratory Services	-	-	-	-	-	-	-	289.21M	283.47M
Laboratory Services Growth	-	-	-	-	-	-	-	-	-1.99%

Revenue by Geography

	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	8.26M	9.02M	12.58M	25.01M	415.33M	978.98M	603.15M	268.98M	259.13M
UNITED STATES Growth	-	9.28%	39.39%	98.86%	1560.41%	135.71%	-38.39%	-55.40%	-3.66%
Non-US	-	-	-	-	-	-	15.82M	20.24M	24.34M
Non-US Growth	-	-	-	-	-	-	-	27.91%	20.27%
CHINA	3.24M	2.61M	109K	-	-	-	-	-	12.64M
CHINA Growth	-	-19.35%	-95.83%	-	-	-	-	-	-
Other Countries	2.98M	3M	4.68M	5.27M	4.65M	-	-	-	11.7M
Other Countries Growth	-	0.74%	55.91%	12.61%	-11.69%	-	-	-	-
Non Us	-	-	-	-	-	13.61M	-	-	-
Non Us Growth	-	-	-	-	-	-	-	-	-
CANADA	3.8M	4.09M	3.98M	2.25M	1.73M	-	-	-	-
CANADA Growth	-	7.71%	-2.62%	-43.65%	-23.16%	-	-	-	-

Frequently Asked Questions

Growth & Financials

Fulgent Genetics, Inc. (FLGT) reported $315.5M in revenue for fiscal year 2024. This represents a 24591% increase from $1.3M in 2014.

Fulgent Genetics, Inc. (FLGT) saw revenue decline by 2.0% over the past year.

Fulgent Genetics, Inc. (FLGT) reported a net loss of $43.0M for fiscal year 2024.

Dividend & Returns

Fulgent Genetics, Inc. (FLGT) has a return on equity (ROE) of -3.8%. Negative ROE indicates the company is unprofitable.

Fulgent Genetics, Inc. (FLGT) had negative free cash flow of $19.8M in fiscal year 2024, likely due to heavy capital investments.